- Home
- HYPR vs XGN Comparison
HYPR vs XGN Comparison
Compare HYPR & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYPR | XGN |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.9M | 110.8M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HYPR | XGN |
|---|---|---|
| Price | $1.07 | $3.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $1.28 | ★ $11.00 |
| AVG Volume (30 Days) | 286.6K | ★ 393.4K |
| Earning Date | 04-20-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.68 | ★ 38.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,890,000.00 | N/A |
| Revenue This Year | $5.96 | $21.40 |
| Revenue Next Year | $34.43 | $14.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.84 | N/A |
| 52 Week Low | $0.53 | $2.67 |
| 52 Week High | $2.22 | $12.23 |
Technical Indicators
Market Signals| Indicator | HYPR | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 39.34 |
| Support Level | $1.05 | $3.15 |
| Resistance Level | $1.19 | $7.29 |
| Average True Range (ATR) | 0.06 | 0.27 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 28.57 | 52.94 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.